CN107049992A - 一种egcg微丸胶囊及其制备方法 - Google Patents
一种egcg微丸胶囊及其制备方法 Download PDFInfo
- Publication number
- CN107049992A CN107049992A CN201710396375.8A CN201710396375A CN107049992A CN 107049992 A CN107049992 A CN 107049992A CN 201710396375 A CN201710396375 A CN 201710396375A CN 107049992 A CN107049992 A CN 107049992A
- Authority
- CN
- China
- Prior art keywords
- egcg
- micro pill
- preparation
- capsules
- fluid bed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 139
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 239000002775 capsule Substances 0.000 title claims abstract description 67
- 239000006187 pill Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000012530 fluid Substances 0.000 claims abstract description 25
- 239000002702 enteric coating Substances 0.000 claims abstract description 19
- 238000009505 enteric coating Methods 0.000 claims abstract description 19
- 239000008188 pellet Substances 0.000 claims abstract description 17
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 239000011162 core material Substances 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 7
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 102
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 8
- 235000005487 catechin Nutrition 0.000 description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 7
- 229950001002 cianidanol Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 150000001253 acrylic acids Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- -1 flavanol compound Chemical class 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical class O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- KPODGGAPCOAOLE-UHFFFAOYSA-N 2-phenyl-3,4-dihydrochromene-2,4-diol Chemical class O1C2=CC=CC=C2C(O)CC1(O)C1=CC=CC=C1 KPODGGAPCOAOLE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种EGCG微丸胶囊及其制备方法,属于保健食品和药物制剂领域。本发明针对EGCG在人体肠胃中滞留时间短、吸收率不高、生物利用率低的问题,提供了一种EGCG微丸胶囊及其制备方法,该微丸胶囊由EGCG微丸丸芯、肠溶包衣和胶囊外壳组成,其中EGCG微丸丸芯包括EGCG、MCC、淀粉和PVPk30。本发明采用流化床制备EGCG微丸,避免胃部酸性条件对EGCG的破坏,延长了EGCG在肠胃中的滞留时间,提高了吸收率和生物利用度;将EGCG微丸再填充于空心胶囊,可隔绝药物与光线、空气接触,提高药物的稳定性,便于贮存、运输和使用。整个制备工艺操作简单,易于控制,适用于工业化生产。
Description
技术领域
本发明涉及一种微丸胶囊及其制备方法,具体涉及一种EGCG微丸胶囊及其制备方法,属于保健食品和药物制剂领域。
背景技术
茶多酚(TP)是茶叶中含量最丰富、最具特征性的次生代谢产物,包括黄烷醇类(又称儿茶素类)、黄酮类(花黄素)、黄酮醇类(黄酮醇及其苷类)、羟基-4-黄烷醇类及其烊盐(花白素、花青素)、酚酸和缩酚酸类以及其他多酚类。儿茶素类是茶叶中主要的多酚类物质,其中含量较高的几种儿茶素是:表没食子儿茶素没食子酸酯(EGCG)、表儿茶素没食子酸酯(ECG)、表没食子儿茶素(EGC)、表儿茶素(EC)、没食子儿茶素没食子酸酯(GCG)、儿茶素(C)、没食子儿茶素(GC)等。
表没食子儿茶素没食子酸酯(EGCG),是绿茶茶多酚中含量最丰富的儿茶素,约占儿茶素质量的50%,因其较强的生物活性而备受关注。近年来,多项体内外实验证实,EGCG具有抗氧化、清除自由基、抗炎症、抗肿瘤、预防癌症、防紫外线、预防血管疾病、预防肥胖等功效。作为毒副作用小的食源性天然活性物质,EGCG的开发和应用有着很好的前景。
但是,EGCG因其酚羟基有很强的供氢能力,易被氧化生成邻醌类及联苯酚醌物质,且易受体液影响而降解,因此稳定性比较差,导致EGCG在人体肠胃中滞留时间短、吸收率不高、生物利用率低,大大影响了EGCG广泛的应用。因此,保持EGCG的稳定性对维持其生物活性、提高生物利用率有着重要的意义。
发明内容
本发明针对EGCG在人体肠胃中滞留时间短、吸收率不高、生物利用率低的问题,提供了一种EGCG微丸胶囊及其制备方法,该EGCG微丸胶囊延长了EGCG在人体肠胃中滞留时间,提高了吸收率和生物利用度,以及提高了EGCG在贮存、运输等过程中的稳定性。
为了解决上述技术问题,本发明提供了一种EGCG微丸胶囊,由EGCG微丸丸芯、肠溶包衣和胶囊外壳组成,所述微丸丸芯外侧包裹肠溶包衣后,装载在胶囊外壳中;
所述EGCG微丸丸芯包括以下重量份的组分:
EGCG 20~24份、微晶纤维素(以下简称MCC)15~30份、淀粉15~30份和聚维酮k30(以下简称PVPk30)1~2份;
所述EGCG的纯度≥95%;
所述MCC的粒径为50~100μm;
所述肠溶包衣为水性丙烯酸树脂,质量为EGCG微丸丸芯质量的10~20%;
所述胶囊外壳为符合制药要求的0号、1号或2号空心胶囊壳。
进一步地,所述EGCG的纯度≥98%。
进一步地,所述EGCG的纯度≥99%。
进一步地,所述胶囊外壳为符合制药要求的1号空心胶囊壳。
上述EGCG微丸胶囊的制备方法,包括以下步骤:
(1)取MCC和淀粉,过100目筛混匀,置流化床中,调节流化床参数:主风风量32~38Hz、雾化压力1.2MPa~1.5MPa、供液速度1.0~1.2Hz,用包含PVPk30的EGCG包衣液进行包衣,然后在38~40℃下干燥30~60min,过18~24目筛,得EGCG微丸丸芯;
(2)取步骤(1)的EGCG微丸丸芯置流化床中,50~55℃预热10~20min,调节流化床参数:主风风量50~55Hz、主风温度50~60℃、雾化压力1.2~1.5MPa、供液速度1.2~1.5Hz,用肠溶包衣液包衣,然后在38~40℃下干燥30~60min,过18~24目筛,得EGCG微丸;
(3)将步骤(2)的EGCG微丸装入1号空心胶囊壳中,每粒装量0.32~0.38g,得EGCG微丸胶囊。
进一步地,步骤(1)所述EGCG包衣液的制备方法为:取PVPk30,加50~70%乙醇溶解,使PVPk30浓度为8%~10%,过100目筛,加入EGCG粉末,搅拌使溶解。
进一步地,步骤(1)所述流化床参数为:主风风量35Hz,雾化压力1.4MPa,供液速度1.1Hz。
进一步地,步骤(2)所述肠溶包衣液的制备方法为:取水性丙烯酸树脂,加4~5倍质量去离子水溶解,混合,过60目筛。
进一步地,步骤(2)所述流化床参数为:主风风量52Hz,主风温度55℃,雾化压力1.4MPa,供液速度1.3Hz。
进一步地,步骤(3)所述空心胶囊壳中每粒EGCG微丸装量为0.35g。
本发明取得的有益效果:
本发明将EGCG制备成微丸,相比于将药物以粉末或颗粒状态直接填装于胶囊壳中,延长了EGCG在肠胃中的滞留时间;将EGCG微丸包肠溶衣后,避免胃部酸性条件对EGCG的破坏,提高生物利用度;将EGCG微丸再填充于空心胶囊,可隔绝药物与光线、空气接触,起到防氧、防潮和避光作用,从而提高药物的稳定性,便于生产、贮存、运输和使用;整个制备工艺操作简单,易于控制,适用于工业化生产。
为了进一步证明本申请所述产品的效果,申请人还分别进行了以下试验及分析:
试验例1 EGCG微丸胶囊稳定性试验
取EGCG粉末和实施例1~3制备的EGCG微丸胶囊,分别均匀地平摊于洁净的培养皿中,放入恒温恒湿培养箱,分别于光照度4500Lx±500Lx,60℃,相对湿度为95%+5%、温度为25℃下放置10天。在第5天和第10天分别取样进行检测,检测项目有外观性状和EGCG含量。
实验结果表明,实施例1~3制备的EGCG微丸胶囊具有良好的稳定性。在光照条件下,EGCG粉末颜色变化明显,由白色变成粉色,EGCG微丸颜色变化不大;高温试验中,在60℃条件下,EGCG微丸胶囊第10天的含量检测结果在规定的限度之内(±10%),EGCG粉末含量损失率较高(见表1);高湿度试验中,EGCG微丸胶囊10天的增湿为2.4%,小于5%,EGCG粉末吸湿严重。
表1 EGCG微丸胶囊及EGCG粉末含量损失率(%)
试验例2 EGCG微丸胶囊生物利用度试验
取健康Beagle犬6只(沈阳康平实验动物研究所),雌雄各半,体重12.12±1.2kg,试验前未服用过其他药物,随机分为2组,每组3只。采用二制剂、二周期的交叉试验设计方法,分别每天口服给予本发明制备的EGCG微丸胶囊(100mg/粒)和EGCG普通粉剂(100mg),连续给药3天,间隔7天后两种药剂交叉再持续给药3天。分别于给药后0h、0.5h、1h、2h、3h、4h、6h、8h、10h、12h、24h、48h、72h时间点下肢静脉采血3mL,检测血浆中EGCG含量,并绘制血浆EGCG浓度-时间曲线,利用3P97药物动力学软件计算血浆EGCG浓度-时间曲线下面积(AUC)。
第一周期给予制备的EGCG微丸胶囊和EGCG粉剂后,不同时间点血浆EGCG浓度-时间数据见表2,根据3P97药物动力学软件计算可知EGCG微丸胶囊试验组AUC为9239.31mg·h/L;而EGCG粉剂对照组,计算所得AUC为313.22mg·h/L。
表2第一周期给药后不同时间EGCG血药浓度(ng/mL)
第二周期给予实施例3制备的EGCG微丸胶囊和EGCG粉剂后,不同时间点血浆EGCG浓度-时间数据见表3,根据3P97药物动力学软件计算可知EGCG微丸胶囊试验组AUC为9839.31mg·h/L;而EGCG粉剂对照组,计算所得AUC为365.89mg·h/L。综上,EGCG微丸胶囊提高了EGCG的生物利用度。
表3第二周期给药后不同时间EGCG血药浓度(ng/mL)
具体实施方式
下面结合实施例进一步详细说明本发明技术方案。采用的空心胶囊壳购自湖南尔康制药股份有限公司,采用的肠溶包衣购自卡乐康北京技术有限公司,采用的EGCG粉末购自湖南三为生物科技有限公司。
实施例1一种EGCG微丸胶囊的制备方法,包括以下步骤:
(1)取5g PVPk30,加50mL 50%乙醇溶解,使PVPk30浓度为10%,过100目筛,加入100g纯度95%的EGCG粉末,搅拌使溶解,得到EGCG包衣液;取75g MCC和75g淀粉,过100目筛混匀,置流化床中,调节流化床各项参数:主风风量32Hz,雾化压力1.2MPa,供液速度1.2Hz,用EGCG包衣液进行包衣,然后在40℃下干燥30min,过18目筛,得EGCG微丸丸芯;
(2)取25.5g水性丙烯酸肠溶包衣(卡乐康北京技术有限公司),加100mL去离子水溶解,用磁力搅拌器充分混合,过60目筛,得到肠溶包衣液;取步骤(1)的EGCG微丸丸芯置流化床中,50℃预热20min,调节流化床各项参数:主风风量50Hz,主风温度60℃,雾化压力1.2MPa,供液速度1.5Hz。用肠溶包衣液包衣,然后在38℃下干燥60min,过18目筛,得EGCG微丸;
(3)将步骤(2)的EGCG微丸装入0号空心胶囊壳中,每粒装量0.38g,得EGCG微丸胶囊。
实施例2一种EGCG微丸胶囊的制备方法,包括以下步骤:
(1)取10g PVPk30,加125mL 70%乙醇溶解,PVPk30浓度为8%,过100目筛,加入120g纯度98%的EGCG,搅拌使溶解,得到EGCG包衣液;取150gMCC和150g淀粉,过100目筛混匀,置流化床中,调节流化床各项参数:主风风量38Hz,雾化压力1.5MPa,供液速度1.0Hz,用EGCG包衣液进行包衣,然后在38℃下干燥60min,过24目筛,得EGCG微丸丸芯;
(2)取86g水性丙烯酸肠溶包衣(卡乐康北京技术有限公司),加430mL去离子水溶解,用磁力搅拌器充分混合,过60目筛,得到肠溶包衣液;取步骤(1)的EGCG微丸丸芯置流化床中,55℃预热10min,调节流化床各项参数:主风风量55Hz,主风温度50℃,雾化压力1.5MPa,供液速度1.2Hz。用肠溶包衣液包衣,然后在40℃下干燥30min,过24目筛,得EGCG微丸;
(3)将步骤(2)的EGCG微丸装入2号空心胶囊壳中,每粒装量0.32g,得EGCG微丸胶囊。
实施例3一种EGCG微丸胶囊的制备方法,包括以下步骤:
(1)取10g PVPk30,加125mL 70%乙醇溶解,PVPk30浓度为8%,过100目筛,加入120g纯度99%的EGCG,搅拌使溶解,得到EGCG包衣液;取150gMCC和150g淀粉,过100目筛混匀,置流化床中,调节流化床各项参数:主风风量35Hz,雾化压力1.4MPa,供液速度1.1Hz,用EGCG包衣液进行包衣,然后在38℃下干燥60min,过24目筛,得EGCG微丸丸芯;
(2)取86g水性丙烯酸肠溶包衣(卡乐康北京技术有限公司),加430mL去离子水溶解,用磁力搅拌器充分混合,过60目筛,得到肠溶包衣液;取步骤(1)的EGCG微丸丸芯置流化床中,55℃预热10min,调节流化床各项参数:主风风量52Hz,主风温度55℃,雾化压力1.4MPa,供液速度1.3Hz。用肠溶包衣液包衣,然后在40℃下干燥30min,过24目筛,得EGCG微丸;
(3)将步骤(2)的EGCG微丸装入1号空心胶囊壳中,每粒装量0.35g,得EGCG微丸胶囊。
Claims (10)
1.一种EGCG微丸胶囊,其特征在于,由EGCG微丸丸芯、肠溶包衣和胶囊外壳组成,所述微丸丸芯外侧包裹肠溶包衣后,装载在胶囊外壳中;
所述EGCG微丸丸芯包括以下重量份的组分:
EGCG 20~24份、微晶纤维素15~30份、淀粉15~30份和聚维酮k30 1~2份;
所述EGCG的纯度≥95%;
所述微晶纤维素的粒径为50~100μm;
所述肠溶包衣为水性丙烯酸树脂,质量为EGCG微丸丸芯质量的10~20%;
所述胶囊外壳为符合制药要求的0号、1号或2号空心胶囊壳。
2.根据权利要求1所述的EGCG微丸胶囊,其特征在于,所述EGCG的纯度≥98%。
3.根据权利要求2所述的EGCG微丸胶囊,其特征在于,所述EGCG的纯度≥99%。
4.根据权利要求1所述的EGCG微丸胶囊,其特征在于,所述胶囊外壳为符合制药要求的1号空心胶囊壳。
5.一种权利要求1所述的EGCG微丸胶囊的制备方法,其特征在于,所述方法包括以下步骤:
(1)取微晶纤维素和淀粉,过100目筛混匀,置流化床中,调节流化床参数:主风风量32~38Hz、雾化压力1.2MPa~1.5MPa、供液速度1.0~1.2Hz,用包含聚维酮k30的EGCG包衣液进行包衣,然后在38~40℃下干燥30~60min,过18~24目筛,得EGCG微丸丸芯;
(2)取步骤(1)的EGCG微丸丸芯置流化床中,50~55℃预热10~20min,调节流化床参数:主风风量50~55Hz、主风温度50~60℃、雾化压力1.2~1.5MPa、供液速度1.2~1.5Hz,用肠溶包衣液包衣,然后在38~40℃下干燥30~60min,过18~24目筛,得EGCG微丸;
(3)将步骤(2)的EGCG微丸装入空心胶囊壳中,每粒装量0.32~0.38g,得EGCG微丸胶囊。
6.根据权利要求5所述的EGCG微丸胶囊的制备方法,其特征在于,步骤(1)所述EGCG包衣液的制备方法为:取聚维酮k30,加50~70%乙醇溶解,使聚维酮k30浓度为8%~10%,过100目筛,加入EGCG粉末,搅拌使溶解。
7.根据权利要求5所述的EGCG微丸胶囊的制备方法,其特征在于,步骤(1)所述流化床参数为:主风风量35Hz,雾化压力1.4MPa,供液速度1.1Hz。
8.根据权利要求5所述的EGCG微丸胶囊的制备方法,其特征在于,步骤(2)所述肠溶包衣液的制备方法为:取水性丙烯酸树脂,加4~5倍质量去离子水溶解,混合,过60目筛。
9.根据权利要求5所述的EGCG微丸胶囊的制备方法,其特征在于,步骤(2)所述流化床参数为:主风风量52Hz,主风温度55℃,雾化压力1.4MPa,供液速度1.3Hz。
10.根据权利要求5、7、9中任一项所述的EGCG微丸胶囊的制备方法,其特征在于,步骤(3)所述空心胶囊壳中每粒EGCG微丸装量为0.35g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710396375.8A CN107049992A (zh) | 2017-05-31 | 2017-05-31 | 一种egcg微丸胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710396375.8A CN107049992A (zh) | 2017-05-31 | 2017-05-31 | 一种egcg微丸胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107049992A true CN107049992A (zh) | 2017-08-18 |
Family
ID=59616046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710396375.8A Pending CN107049992A (zh) | 2017-05-31 | 2017-05-31 | 一种egcg微丸胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107049992A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108391816A (zh) * | 2017-02-08 | 2018-08-14 | 阙燕娣 | 一种抗氧化保健胶囊的生产方法 |
CN109864982A (zh) * | 2019-03-22 | 2019-06-11 | 大连医诺生物股份有限公司 | 表没食子儿茶素没食子酸酯微囊粉及其制备方法 |
CN113171380A (zh) * | 2021-04-30 | 2021-07-27 | 浙江育康清生物医药有限公司 | 一种中药组合物及其应用 |
WO2022098879A1 (en) * | 2019-05-06 | 2022-05-12 | Axial Therapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257469A1 (en) * | 2005-04-05 | 2006-11-16 | Bulka Yochanan R | Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase |
CN101167719A (zh) * | 2007-11-02 | 2008-04-30 | 广东省实验动物监测所 | 表没食子儿茶素没食子酸酯微囊颗粒及其制备工艺 |
CN101219136A (zh) * | 2007-12-11 | 2008-07-16 | 北京协和建昊医药技术开发有限责任公司 | 一种预防和治疗艾滋病的口服胶囊剂及其制备方法 |
JP2009084266A (ja) * | 2007-09-14 | 2009-04-23 | Osaka Univ | エピガロカテキンガレートのアシル誘導体を利用した抗癌剤 |
CN101869633A (zh) * | 2009-04-24 | 2010-10-27 | 南京苏中药物研究有限公司 | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 |
US20100303904A1 (en) * | 2007-07-30 | 2010-12-02 | Bio-Pro Medical Ltd. | Tablet with remedial composition and methods for treating medical disorders and ailments |
CN103705704A (zh) * | 2013-10-14 | 2014-04-09 | 北京天安康健生物科技有限公司 | 具有降脂功能的红曲蒜粉保健品及其应用 |
US20140314860A1 (en) * | 2013-04-23 | 2014-10-23 | Zx Pharma Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
CN104857303A (zh) * | 2015-05-27 | 2015-08-26 | 侯苏 | 一种治疗小儿湿疹的药物的制备方法 |
-
2017
- 2017-05-31 CN CN201710396375.8A patent/CN107049992A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257469A1 (en) * | 2005-04-05 | 2006-11-16 | Bulka Yochanan R | Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase |
US20100303904A1 (en) * | 2007-07-30 | 2010-12-02 | Bio-Pro Medical Ltd. | Tablet with remedial composition and methods for treating medical disorders and ailments |
JP2009084266A (ja) * | 2007-09-14 | 2009-04-23 | Osaka Univ | エピガロカテキンガレートのアシル誘導体を利用した抗癌剤 |
CN101167719A (zh) * | 2007-11-02 | 2008-04-30 | 广东省实验动物监测所 | 表没食子儿茶素没食子酸酯微囊颗粒及其制备工艺 |
CN101219136A (zh) * | 2007-12-11 | 2008-07-16 | 北京协和建昊医药技术开发有限责任公司 | 一种预防和治疗艾滋病的口服胶囊剂及其制备方法 |
CN101869633A (zh) * | 2009-04-24 | 2010-10-27 | 南京苏中药物研究有限公司 | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 |
US20140314860A1 (en) * | 2013-04-23 | 2014-10-23 | Zx Pharma Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
CN103705704A (zh) * | 2013-10-14 | 2014-04-09 | 北京天安康健生物科技有限公司 | 具有降脂功能的红曲蒜粉保健品及其应用 |
CN104857303A (zh) * | 2015-05-27 | 2015-08-26 | 侯苏 | 一种治疗小儿湿疹的药物的制备方法 |
Non-Patent Citations (1)
Title |
---|
潘卫三: "《工业药剂学》", 31 August 2015, 中国医药科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108391816A (zh) * | 2017-02-08 | 2018-08-14 | 阙燕娣 | 一种抗氧化保健胶囊的生产方法 |
CN109864982A (zh) * | 2019-03-22 | 2019-06-11 | 大连医诺生物股份有限公司 | 表没食子儿茶素没食子酸酯微囊粉及其制备方法 |
WO2022098879A1 (en) * | 2019-05-06 | 2022-05-12 | Axial Therapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
US11883537B2 (en) | 2019-05-06 | 2024-01-30 | Axial Therapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
CN113171380A (zh) * | 2021-04-30 | 2021-07-27 | 浙江育康清生物医药有限公司 | 一种中药组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107049992A (zh) | 一种egcg微丸胶囊及其制备方法 | |
JP6598841B2 (ja) | ツーピース硬カプセル用の耐酸性バンド溶液 | |
CN105410943A (zh) | 一种复合维生素片及其制备方法 | |
RU2414211C2 (ru) | Композиция с пролонгированным высвобождением активного вещества, способ ее получения и применение | |
CN102573496A (zh) | 缓释镁组合物及其用途 | |
CN106692096B (zh) | 一种复合维生素缓释片胶囊 | |
EP2665467A2 (en) | Flavonol compositions | |
CN102579318A (zh) | 稳定的维生素c缓释制剂及其制备方法 | |
CN106822033A (zh) | 以玉米芯粉为囊心材料制备含药物的囊心物及其微囊 | |
CN107789335B (zh) | 青蒿素微胶囊的制备方法 | |
CN111568865B (zh) | 一种纳米晶颗粒及其制备方法 | |
CN102210658B (zh) | 高含量α-亚麻酸微囊软胶囊制剂 | |
CN101590021A (zh) | 头孢呋辛酯掩味微丸及制备方法 | |
CN103565778A (zh) | 叶黄素微胶囊及其制备方法 | |
CN106822034A (zh) | 以玉米芯粉为囊心材料制备含药物的囊心物或微囊 | |
CN103690510B (zh) | 一种纳米级纤维素空心硬胶囊及其制备方法 | |
UA122198C2 (uk) | Екстракт danshen, склад на його основі у формі мікропелет, склад у формі капсули з мікропелетами, одержаний з нього, способи його одержання та застосування | |
CN106265583B (zh) | 一种帕利哌酮释放速率递增制剂及其制备方法 | |
CN101088505A (zh) | 灯盏花素聚合物纳米粒制剂及其制备方法 | |
CN113694847A (zh) | 一种维生素b12微胶囊片剂的制备方法 | |
CN110237038A (zh) | 一种nadh载药微球 | |
CN102552208A (zh) | 黄豆苷元固体分散微丸胶囊及其制备方法 | |
CN103040761B (zh) | 一种盐酸二甲双胍缓释小丸制剂及其制备方法 | |
CN102144985B (zh) | 一种氯化钾单室渗透泵控释片及其制备方法 | |
CN102283984A (zh) | 一种瓜蒌薤白白酒汤整合型新剂型制备技术 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |